Dynavax Technologies Corporation
DVAX
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufactures and sells CpG 1018, the adjuvant used in HEPLIā¦ read more
Healthcare
Drug ManufacturersāSpecialty & Generic
21 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$10.86
Price-0.09%
-$0.01
1Y
Price
Market Cap
$1.275b
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years+33.6%
EBITDA Margin+28.4%
Net Profit Margin+34.4%
Free Cash Flow MarginRevenue
$330.514m
+19.2%
1y CAGR-9.8%
3y CAGR+8.8%
5y CAGREarnings
-$43.401m
-258.9%
1y CAGR+55.4%
3y CAGR+112.1%
5y CAGREPS
-$0.37
-285.0%
1y CAGR+37.5%
3y CAGR+89.5%
5y CAGRBook Value
$534.138m
$946.506m
Assets$412.368m
Liabilities$285.024m
DebtDebt to Assets
30.1%
-11.1x
Debt to EBITDAFree Cash Flow
$80.537m
+33.9%
1y CAGR+23.3%
3y CAGR-3.3%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company